The wolf of hypomethylating agent failure: what comes next?
作者信息
Kubasch Anne Sophie, Platzbecker Uwe
机构信息
Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Germany.
German MDS Study Group (G-MDS).
出版信息
Haematologica. 2019 Aug;104(8):1505-1508. doi: 10.3324/haematol.2019.222794.
Abstract
摘要
相似文献
1
The wolf of hypomethylating agent failure: what comes next?低甲基化剂治疗失败的困境：接下来该何去何从？
Haematologica. 2019 Aug;104(8):1505-1508. doi: 10.3324/haematol.2019.222794.
2
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
3
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.阿扎胞苷治疗失败后，骨髓增生异常综合征和急性髓系白血病对地西他滨缺乏客观反应。
Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.
4
The euphoria of hypomethylating agents in MDS and AML: is it justified?低甲基化药物在 MDS 和 AML 中的兴奋：这合理吗？
Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.
5
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.一项关于伏立诺他联合地西他滨治疗急性髓系白血病或骨髓增生异常综合征患者的 1 期临床试验。
Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8.
6
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.阿扎胞苷：在骨髓增生异常综合征和急性髓系白血病中的综述。
Drugs. 2016 May;76(8):889-900. doi: 10.1007/s40265-016-0585-0.
7
Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.急性髓系白血病伴骨髓增生异常相关改变患者经去甲基化药物治疗后出现17号染色体等臂染色体的病例报告。
Genet Mol Res. 2012 Aug 6;11(3):2045-50. doi: 10.4238/2012.August.6.8.
8
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.急性髓细胞白血病或骨髓增生异常综合征中低甲基化药物临床反应的预测因素。
Ann Hematol. 2018 Nov;97(11):2025-2038. doi: 10.1007/s00277-018-3464-9. Epub 2018 Aug 6.
9
[Biomarkers predicting the efficacy of DNA hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia: TET enzymes].预测DNA低甲基化药物治疗骨髓增生异常综合征和急性髓系白血病疗效的生物标志物：TET酶
Rinsho Ketsueki. 2018;59(5):594-601. doi: 10.11406/rinketsu.59.594.
10
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?阿扎胞苷联合来那度胺治疗骨髓增生异常综合征或急性髓系白血病——明智的联合？
Leukemia. 2013 Sep;27(9):1813-9. doi: 10.1038/leu.2013.140. Epub 2013 May 6.
引用本文的文献
1
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine.高水平的整体羟甲基化预示着接受阿扎胞苷治疗的骨髓增生异常综合征（MDS）患者的总生存期更差。
Hemasphere. 2025 Jan 3;9(1):e70034. doi: 10.1002/hem3.70034. eCollection 2025 Jan.
2
Development of luspatercept to treat ineffective erythropoiesis.开发芦司他丁治疗无效红细胞生成。
Blood Adv. 2021 Mar 9;5(5):1565-1575. doi: 10.1182/bloodadvances.2020002177.
3
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.地西他滨联合小剂量阿糖胞苷用于不适合治疗的复发性或难治性急性髓系白血病患者的门诊治疗。
Ann Hematol. 2021 May;100(5):1195-1202. doi: 10.1007/s00277-021-04471-6. Epub 2021 Mar 4.
本文引用的文献
1
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.一项关于地西他滨治疗阿扎胞苷治疗失败后的高危骨髓增生异常综合征和低原始细胞数急性髓系白血病的 II 期研究。
Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.
2
Treatment of MDS.骨髓增生异常综合征的治疗。
Blood. 2019 Mar 7;133(10):1096-1107. doi: 10.1182/blood-2018-10-844696. Epub 2019 Jan 22.
3
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.阿扎胞苷和纳武利尤单抗治疗复发/难治性急性髓系白血病的疗效、安全性和生物标志物：一项非随机、开放标签、Ⅱ期研究。
Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.
4
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
5
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.Quizartinib，一种 FLT3 抑制剂，作为复发或难治性急性髓系白血病患者的单药治疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
6
Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.帕博利珠单抗治疗黑色素瘤合并急性髓系白血病的临床、分子和免疫反应。
Blood Adv. 2018 Jun 12;2(11):1187-1190. doi: 10.1182/bloodadvances.2017014811.
7
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
8
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.阿扎胞苷治疗急性髓系白血病的疗效不受同时给予伏立诺他治疗的影响，但可由诊断性分子特征预测。
Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.
9
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。 （注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平 ，以下按照正确药物名给出译文）
恩西地平用于治疗突变型复发或难治性急性髓系白血病。
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
10
The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications.人类髓系恶性肿瘤的微环境：新出现的概念和治疗意义。
Blood. 2017 Mar 23;129(12):1617-1626. doi: 10.1182/blood-2016-11-696070. Epub 2017 Feb 3.
Zotero 插件